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Purpose: Terminalia glaucescens (Combretaceae) is traditionally used in Cameroon in the treatment of 
diabetes. The anti-hyperglycemic effect of the methanol-methylene chloride extract of the leaves of this 
plant was investigated in streptozotocin (STZ)-induced diabetic mice.  
Methods: Diabetes was induced in mice by a daily dose of STZ (45 mg kg
-1
 body weight i.p.) for 5 days. 
From one day before STZ injection, normal and diabetic-test mice received one oral dose of the extract 
(100 mg kg
-1
 or 300 mg kg
-1
 body weight) daily for 15 days. The effect of the extract on body weight 
gain, food and water intake, plasma metabolites (glucose and lipids) and insulin levels was investigated. 
Results: Diabetic control mice and diabetic mice pre-treated with 100 mg kg
-1
 extract showed body 
weight loss, marked (P< 0.001) polyphagia and polydipsia, high plasma metabolites and glucose (P< 
0.001), non-esterified fatty acids (NEFA) (P< 0.05), triglycerides (TG) (P< 0.05), and cholesterol (P< 
0.05) and low insulin (P< 0.001) levels. Normal control, i.e., normal treated mice and 300 mg kg
-1
 extract 
pre-treated diabetic mice, presented normal weight gain, normal food and water intake, normal plasma 
metabolites and insulin levels, and did not exhibit very significant changes (P<0.1) in blood glucose 
level.. 
Conclusion: These results indicate that the extract of T. glaucescens leaf at a dose of 300 mg kg
-1
 
protects against STZ-induced diabetic effects and could explain the traditional use of this plant in the 
management of diabetes. 
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INTRODUCTION 
 
Diabetes mellitus is a metabolic disorder 
characterized by fasting hyperglycemia and 
alterations in carbohydrate, fat and protein 
metabolism, associated with absolute or 
relative deficiencies in insulin secretion and/or 
insulin action
1
. As the number of people with 
diabetes multiplies worldwide, the disease has 
taken an ever-increasing share of national and 
international health budgets. Type 1 diabetes 
is an auto-immune disease characterized by a 
local inflammatory reaction in and around 
pancreatic islets that is followed by selective 
destruction of insulin-secreting  cells
2-4
. 
Experimentally, streptozotocin (STZ) or 
alloxan are used to induce diabetes in 
rodents. STZ is effective in triggering islet cell 
death by acute oxidative stress. STZ-induced 
diabetic mice are one of the animal models of 
insulin-dependent diabetes mellitus 
characterized by high fasting blood glucose 





Though different types of oral hypoglycemic 
agents are available along with insulin for the 
management of diabetes mellitus, there is a 
growing interest in herbal remedies due to the 
side effects associated with orthodox 
therapeutic agents
6,7
. Furthermore, plants 
have played a major role in the discovery of 
new therapeutic agents. A medicinal plant, 
Galega officinalis, led to the discovery and 
synthesis of metformin; however, there is still 





The available literature shows that there are 
more than 400 plant species showing 
antidiabetic activities
10-12
. The protective effect 
of some plants or natural substances against 
the death of  cells has been reported
13
. 
Information provided by practitioners of 
traditional medicine in the Centre Province of 
Cameroon suggests that Terminalia 
glaucescens possesses useful anti-diabetic 
properties, although this was not cited in the 
national ethnobotanical survey of 
Cameroonian medicinal plants. Terminalia 
arjuna, Terminalia belerica, Terminalia 
chebula, Terminalia catappa and Terminalia 
pallida are other species of the same family 





The present study was undertaken to 
investigate the anti-hyperglycemia effect of 
the methanol/methylene chloride extract of 
Terminalia glaucescens leaf on the 
hyperglycemia induced by a multiple dose of 
STZ in diabetic mice. 
 




Fresh leaves of Terminalia glaucescens were 
harvested in October 2005 in Mbalmayo in the 
Centre Province of Cameroon. T. glaucescens 
was identified by Dr Simeon Tchoulagueu of 
the Teachers' Training College of the 
University of Yaoundé I, who kept a voucher 
specimen (no. 4016/BS) in the laboratory. 
Two kilograms of the sun-dried powdered 
leaves were macerated in a mixture of 
methanol/methylene chloride (1:1) for 7 days 
(with occasional stirring) at room temperature. 
The mixture was filtered with Whatman No.1 
filter paper and the filtrate concentrated in a 
rotary evaporator (Rotavapor) at 45°C to yield 
125g of a dry dark extract. Doses of 20 mg 
mL
-1 
and 60 mg mL
-1
 were obtained by 
dissolving 2 g and 6 g, respectively, of the 
concentrated extract in 100 mL of 10% 
dimethyl sulfoxide (DMSO) solution. The 
experimental dose was 5 µL g
-1
 body weight. 
 
Experimental animals  
 
Male albino Wistar mice (26-30 g weight, 8-10 
weeks old) were raised in the animal house of 
our laboratory under natural conditions with 
free access to water and regular rodent chow. 
For this experiment, the mice were fasted 
overnight prior to blood sugar determination 
and randomly divided into 6 groups of 8 
animals each as follows:  
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- One group of mice (control, NC) received 
10% DMSO p.o. and citrate buffer (Cb) 
i.p.,  
- Two groups of normal mice (NE) were 
treated with 100 mg kg
-1
 body weight 
(NE100) or 300 mg kg
-1
 body weight 
(NE300) plant extract (p.o.) and Cb (i.p.),  
- One group of diabetic mice (diabetic 
control, DC) was treated with DMSO and 
STZ,  
- Two groups of diabetic mice (DE) were 
treated with 100 mg kg
-1
 (DE100) or 300 
mg kg
-1
 (DE300) body weight plant extract 
and STZ. 
 
To induce diabetes, the mice received 45 mg 
kg
-1
 (i.p.) of freshly prepared STZ (Sigma 
Aldrich No. SO 130) dissolved in citrate buffer 
100 mM pH4.5 (Cb) daily for five consecutive 
days. The plant extract was administered to 
the fed mice and STZ injection was preceded 
by 4 h of fasting. Animals DE100 and DE300 
orally received a dose of plant extract, daily 
for five consecutive days, followed 6 hours 
later by i.p. injection of STZ. T. glaucescens 
extract administration began one day (day 0) 
before the beginning of STZ injection and 
continued for up to day 14.  
 
Animal housing and in vivo experiments 
conformed to the guidelines of the European 
Union on Animal Care (CEE Council 86/609) 
and were ethically approved by the 
Institutional Committee of the Ministry of 
Scientific Research and Innovation of 
Cameroon. 
 
Measurement of body weight gain, food 
and water intake 
 
Food and water intake were monitored on 
days 1, 3, 6 and 12 while body weight was 
measured on days 0, 3, 6, 9, 12 and 15. 
 
Determination of blood parameters 
 
Blood samples for glucose determination were 
obtained from the tail tip of 4 h fasted mice on 
days 0, 6 and 12 of the experiment. Blood 
glucose level was estimated using a 
glucometer (Accu-Check, Roche). Mice with 





At the end of the treatment (day 15), mice 
were weighed and anesthetized with sodium 
pentobarbital (60 mg kg
-1
 i.p.). Blood was 
rapidly collected by cardiac puncture in 
syringes containing EDTA. Blood samples 
were centrifuged (1 min, 8000 g), from which 
plasma was collected, aliquoted and snap-
frozen in liquid nitrogen. Plasma parameters 
were assayed using commercially available 
kits according to the manufacturers’ 
instructions: triglycerides (TG: Triglycerides 
PAP, bioMérieux, Marcy l’Etoile, France), non 
esterified fatty acids (NEFA, NEFA-C, Wako), 
and cholesterol (RTU, bioMérieux). Plasma 
insulin levels were measured by 
radioimmunoassay using porcine insulin kit 
(SB-insulin-CT, CIS Biointernational, Gif-sur-
Yvette, France) with guinea pig anti-porcine 
insulin serum-coated tubes. 
 
Statistical analysis 
The results are expressed as mean X  ± 
standard error of mean (S.E.M.). Mean values 
were obtained by one-way analysis of 
variance (ANOVA) using the computer 
software, StatView 4.5, followed by Dunnets 
multiple comparison test. The significance of 
difference between and within various groups 
was determined. Values of P < 0.05 were 




Body weight, food and water intake 
 
There was no significant difference in body 
weight between the groups prior to STZ 
injection. The body weight progressively 
decreased in diabetic control group (DC) and 
diabetic group treated with 100 mg kg
-1
 body 
weight extract (DE100). The decrease was 
significant on days 6 (P< 0.05), and 9 and 15 
(P< 0.001) compared to the normal control 
group (-28% DC and – 25% DE100) as shown 
in Fig 1. Body weight gain for normal control 
(NC), normal treated (NE100 and NE300) and 
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300 mg kg
-1
 treated diabetic (DE300) mice 
increased progressively and were 
comparable. Furthermore, DC and DE100 
presented significant (P < 0.01) increases in 
food and water intake on day 3 which became 
more marked on the 12th day, whereas other 
groups (NC, E100; E300 and DE300) did not 
exhibit significant variations in food and water 
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Figure 1: Body weight of mice (expressed as % of initial body weight ibw = 100 %) within 15 
days of treatment with the extract of Terminalia glaucescens leaf. Key: Normal mice treated with 
100 mg kg
-1
 ( ) and 300 mg kg
-1
 ( ) body weight, diabetic mice pre-treated with 100 mg kg
-1
 
( ) and 300 mg kg
-1
 ( ) body weight extract; normal ( ) and diabetic ( ) control groups 







P< 0.001 compared with NC value; 
c


































































Figure 2: Variations of mice food (FI) and water (WI) intake (expressed as % of initial values 
=100 %) within 12 days of treatment with Terminalia glaucescens leaf extract. Key: 
Normal mice treated with 100 mg kg
-1
 ( ) and 300 mg kg
-1
 ( ) body weight, 
diabetic-test mice pre-treated with 100 mg kg
-1
 ( ) and 300 mg kg
-1
 ( ) extract; 
normal ( ) and diabetic-test ( ) control groups treated with vehicles.  
Data are mean ± S.E.M., n = 8. Significant differences: 
*
P < 0.05, 
**
P < 0.01 and 
***
P < 
0.001 compared with NC values; 
c
P < 0.001 compared with DC values. 
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Plasma metabolites and insulin levels 
 
STZ administration significantly (P < 0.001) 
reduced insulin plasma levels (Fig. 3). T. 
glaucescens at 100 mg kg
-1
 did not prevent 
the decrease of the plasma insulin level. The 
plant extract also did not significantly change 
the insulin level in normal mice (NE100 and 
NE300). STZ did not modify insulin secretion 
in mice treated with 300 mg kg
-1
 extract. In DC 
mice, the observed reduction of insulin 
secretion was accompanied by a significant 
(P< 0.05) increase in all plasma lipids: + 45% 
TG, + 32% NEFA, + 29% cholesterol (Table 
1). T. glaucescens extract reduced the STZ-
induced elevation of plasma lipids in a dose- 
dependent manner. Blood glucose level in DC 
mice was very significantly (P < 0.001) 
increased on the 6th day and beyond (Fig. 4). 
The dose of 100 mg kg
-1 
body weight of the 

































Figure 3: Plasma insulin level after 15 days of treatment with Terminalia glaucescens leaf 
extract. Key: 100 mg kg
-1
 body weight in normal mice (NE100) and in diabetic mice 
(DE100), 300 mg kg
-1
 body weight in normal (NE300) and diabetic mice (DE300) mice; 
normal mice (NC) and diabetic mice (DC) control groups treated with vehicle.  
Data are mean ± S.E.M., n = 8. Significant difference: 
***
P < 0.001 compared with NC 
value; 
c
P< 0.001 compared with DC value. 
 
 
Table 1: Plasma lipid (triglycerids TG, non esterified fatty acids NEFA, cholesterol) levels 
(mmol/L) after 15 days treatment with Terminalia glaucescens leaf extract. Key: 100 mg kg
-1
 
body weight in normal mice (NE100) and in diabetic mice (DE100); , 300 mg kg
-1
 body weight in 
normal mice (NE300) and in diabetic mice (DE300); normal mice (NC) and diabetic control (DC) 
control groups treated with vehicles.  
 



































Results are mean ± S.E.M., (n = 8). Significant differences: 
*




P< 0.01 and 
c
P< 0.001 compared with DC values. 
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Figure 4: Blood glucose level within 12 days of treatment with Terminalia glaucescens leaf 
extract 100 mg kg
-1
 body weight in normal ( ) and diabetic mice ( ), 300 mg kg
-1
 
body weight in normal ( ) and diabetic mice ( ) mice; normal mice ( ) and 
diabetic mice ( ) control groups treated with vehicle.  
Data are mean ± S.E.M., n = 8. Significant difference: 
*
P < 0.05 and 
***
P < 0.001 
compared with NC values; 
c
P< 0.001 compared with DC values. 
 
 
effect in mice which had STZ-induced 
hyperglycemia, but there was a significant fall 
in blood glucose in DE300 mice to the extent 
that glycemia was comparable to NC mice. In 
normal mice, T. glaucescens treatment 
resulted in a decrease of blood glucose levels 
(-9 %) in a dose-dependent manner in NE300 




This study was carried out to assess the 
protective effect of the methanol/methylene 
chloride extract of Terminalia glaucescens leaf 
on impaired glucose level induced by STZ. 
Our results show that intraperitoneal 
administration of multiple doses of STZ (45 
mg kg
-1
 for 5 consecutive days) effectively 
induced diabetes in normal fasted mice as 
reflected by hyperglycemia, polyphagia, 
polydipsia and body weight loss, compared 
with normal control (NC) mice. 
 
The T. glaucescens extract dose of 300 mg 
kg
-1
 body weight significantly inhibited the 
hyperglycemic action of STZ, while the blood 
glucose level of diabetic control was distinctly 
increased (+117%). Streptozotocin induces 
hyperglycemia by selective destruction of 
pancreatic -cells that secrete insulin
9,15
. This 
suggests that the extract (300 mg kg
-1
) may 
prevent decreased insulin secretion by 
protecting -cells against destruction caused 
by STZ. 
 
In the extract-pretreated mice, diabetic 
manifestations after STZ administration were 
reduced, suggesting that the extract may 
involve direct inhibition of STZ. The extract 
may act by competing with STZ for glucose 
associated-receptors on -cell membranes. A 
phytochemical analysis of T. glaucescens has 
revealed the presence of tannin, alkaloids, 
flavonoids, triterpenoids and glucose
16
. The 
anti-hyperglycemic activity of T. glaucescens 
may be due to any one or more of these 
constituents in the extract. STZ is a 2-desoxy-
D-glucose derivative of N-methyl-N-nitroso-
urea
17,18
. Thus, it is possible that the glucose 
moiety of STZ, which can bind to glucose 
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receptors on -cells, may directly compete 




T. glaucescens extract might also have acted 
by increasing the resistance of -cells by a 
direct activation of superoxide dismutase, a 
widely distributed enzyme that scavenges 
superoxide anion radical which may be 
responsible for the toxic effects of STZ
20,21
. 
The secretion of insulin correlated with the 
reduction of glycemia. Moreover, T. 
glaucescens extract in normal mice and 300 
mg kg
-1
 extract in diabetic test mice did not 
increase insulinemia beyond the normal 
control value. This suggests that in diabetes, 
T. glaucescens sensitizes insulin peripheral 
action rather than stimulating insulin secretion. 
T. glaucescens probably lowers blood lipids 
(TG, NEFA, cholesterol) due to improvement 
of peripheral insulin action, while body weight 
loss as well as increase in food consumption 
and the related water intake result from the 
lack of insulin action. 
 
The present study showed high plasma NEFA 
in diabetic mice. Excess plasma NEFA can 
inhibit insulin-stimulated glucose utilization in 
muscle and promote hepatic production of 
glucose
22,23
, whereas reduction of plasma 
NEFA concentration improves glucose 
utilization and the suppression of hepatic 
glucose production by insulin
24,25
. The 
reduction of plasma NEFA may also explain 





The results from this study indicate that T. 
glaucescens extract in STZ-induced diabetes 
could have protective effects. The anti-
hyperglycemia effect of T. glaucescens extract 
in STZ-induced diabetes could explain the 
traditional use of this plant for diabetes 
treatment or management. Further studies are 
required to elucidate the site(s), as well as 
cellular and molecular mechanism of actions 
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